Impact of Middle and Low Dose Atorvastatin on Endothelial Progenitor Cell Function in Patients With Acute Myocardial Ischemia Injury
10.3969/j.issn.1000-3614.2017.07.018
- VernacularTitle:中-低剂量阿托伐他汀对急性心肌缺血性损伤中内皮祖细胞功能的影响
- Author:
Liang WANG
;
Wu ZHONG
;
Muhu CHEN
- Keywords:
Myocardial ischemia;
Endothelial progenitor cells;
Lipid-lowering drug
- From:
Chinese Circulation Journal
2017;32(7):697-700
- CountryChina
- Language:Chinese
-
Abstract:
To explore the impact of middle and low dose atorvastatin on peripheral endothelial progenitor cells (EPCs) in patients with acute myocardial ischemia injury via investigating EPC proliferation, migration, differentiation and secretion of cytokines. Method: A total of 80 patients with acute ST-segment elevation myocardial infarction (STEMI) were randomly divided into 2 groups: Observation group, the patients received atorvastatin 40 mg and Control group, the patients received atorvastatin 20 mg. n=40 in each group. The number of circulating EPC, EPC proliferation ability and the secretion of cytokines before and at different time points after drug therapy were examined by means of MTT, flow cytometry and ELISA. Results: The number of EPC was obviously increased with greatly changed migration ability within 2 weeks atorvastatin treatment in both groups. The secretion of cytokines presented that the contents of VEGF, bFGF, CXCR were elevating first followed by reducing thereafter, while the content of SIRT1was continuously increasing during the period of treating. The above parameters were similar between 2 groups. Conclusion: Middle and low dose atorvastatin could effectively improve EPC proliferation and migration, increase the expressions of CXCR4, VEGF, bFGF and SIRT1 in STEMI patients.
